Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HDM7005
- Development stage
- Phase 1
- Lead developer
- Huadong Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HDM7005 is an investigational, orally bioavailable small molecule inhibitor of coagulation factor XIa (FXIa) developed by Huadong Medicine (Hangzhou Zhongmei Huadong Pharmaceutical). Factor XIa is a key enzyme in the intrinsic pathway of the coagulation cascade, and its inhibition is hypothesized to provide potent antithrombotic effects while significantly reducing the risk of major bleeding compared to traditional anticoagulants that target the common pathway, such as warfarin or direct factor Xa inhibitors. The drug is currently in Phase 1 clinical development for the prevention and treatment of various thrombotic conditions, including atherosclerosis, ischemic cardiovascular disease, ischemic cerebrovascular disease, and venous thrombosis.
02
Targets
Factor XIa
Beyond the preview
Go deeper on HDM7005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HDM7005.